The authors from The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, investigated the association between cuproptosis, a copper-induced mechanism of mitochondrial-related cell death, and long non-coding RNA (lncRNA) in lung squamous cell carcinoma (LUSC). Cuproptosis has shown potential in cancer treatment, and lncRNAs have been found to play a role in changing the biological activities of tumor cells. Until now, it was not known whether lncRNAs were associated with cuproptosis in LUSC.
LUSC is one of the most difficult tumors to treat, and the authors aimed to develop a signature based on cuproptosis-associated lncRNAs that could predict the prognosis of LUSC and investigate the immunological characteristics of LUSC. The study analyzed 49 normal samples and 502 tumor samples obtained from online databases. The researchers found that a signature consisting of three cuproptosis-related lncRNAs: AC002467.1, LINC01740, and LINC02345, could accurately predict the prognosis of patients with LUSC. Additionally, they used the signature to assess the prognostic risk of patients with LUSC and found that individuals with low-risk scores may benefit from immunotherapy.
The study also found that patients with LUSC who had more mutated risk genes in their bodies had a worse prognosis. These findings suggest that the predictive model based on the three identified lncRNAs is a satisfactory indicator for assessing the prognosis and immunotherapy of LUSC.
The study’s lead authors expressed hope that these findings would lead to further research in drug development against LUSC based on the identified lncRNAs. “I believe it will be very exciting to see the results when they become available,” Qing Lou stated.
The study’s findings have important implications for cancer research and treatment and offer hope for improving outcomes for patients with LUSC.
以下是翻译的文本：
来自中国四川省泸州市西南医科大学附属医院的作者们调查了铜诱导的线粒体相关细胞死亡机制——铜ptosis与长链非编码RNA（lncRNA）在肺鳞状细胞癌（LUSC）中的关联。铜ptosis在癌症治疗中具有潜力，而已经发现lncRNA在改变肿瘤细胞的生物活性方面起到了作用。迄今为止，不清楚lncRNA是否与LUSC中的铜ptosis相关联。
LUSC是最难治疗的肿瘤之一，作者旨在开发基于铜ptosis相关lncRNA的签名，该签名可以预测LUSC的预后并调查LUSC的免疫特性。该研究分析了来自在线数据库的49个正常样本和502个肿瘤样本。研究人员发现，由三个铜ptosis相关lncRNA组成的签名：AC002467.1、LINC01740和LINC02345，可以准确预测患有LUSC的患者的预后。此外，他们使用该签名评估了LUSC患者的预后风险，并发现低风险得分的个体可能从免疫疗法中受益。
该研究还发现，在体内有更多突变风险基因的LUSC患者预后更差。这些发现表明，基于三个已识别的lncRNA的预测模型是评估LUSC的预后和免疫疗法的令人满意的指标。
该研究的主要作者们表示，希望这些发现将促进基于已识别lncRNA的LUSC药物开发的进一步研究。“我相信，当结果可用时，将会非常令人兴奋，”Qing Lou表示。
该研究的发现对癌症研究和治疗具有重要意义，并为改善LUSC患者的预后结果带来了希望。
Reference: Hou C, Wu X, Li C, Wang C, Liu J, Luo Q. A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma. Biomol Biomed [Internet]. 2023Jan.15 [cited 2023Apr.26];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/8481
Editor: Ermina Vukalic
Leave a Reply